SecurityCYTX / Cytori Therapeutics, Inc. (23283K105)
President and CEOHEDRICK MARC H
IndustrySurgical and Medical Instruments and Apparatus
Institutional Owners11
Institutional Shares404,372 - 0.66%
Common Stock Shares Outstanding61,600,000 shares (as of 2018-06-30)
Institutional Value$ 554,000 USD
Related CTYX / Connectyx Technologies Holdings Group, Inc.
CYTXW / Cytori Therapeutics, Inc. Warrants

Institutional Stock Ownership and Shareholders

CYTX / Cytori Therapeutics, Inc. Institutional Ownership

Cytori Therapeutics, Inc. (NASDAQ:CYTX) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 404,372 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, Dimensional Fund Advisors Lp, Macquarie Group Ltd, FNY Partners Fund LP, BlackRock Investment Management, LLC, Ladenburg Thalmann Financial Services Inc, BlackRock Advisors LLC, Fny Investment Advisers, Llc, and Barclays Plc.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR MACQUARIE GROUP LTD 0 40,182 0 29
2018-07-20 13F-HR Creative Planning 78,077 0 -100.00 22 0 -100.00
2018-08-02 13F-HR PERKINS CAPITAL MANAGEMENT INC 2,071,106 0 -100.00 593 0 -100.00
2018-07-30 13F-HR SIMPLEX TRADING, LLC Call 61 0 -100.00 0 0
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 718 0 -100.00 0 0
2017-02-10 13F-HR BlackRock Fund Advisors 33,449 44,201 32.14 68 67 -1.47
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 253,335 253,335 0.00 514 383 -25.49
2018-08-14 13F-HR Intellectus Partners, LLC 30,000 0 -100.00 9 0 -100.00
2018-08-03 13F-HR THOMPSON DAVIS & CO., INC. 34 0 -100.00 0 0
2018-08-14 13F-HR ROYAL BANK OF CANADA 3,231 0 -100.00 1 0 -100.00
2018-07-18 13F-HR Fny Investment Advisers, Llc 1,480 2
2017-02-10 13F-HR BlackRock Advisors LLC 2,594 2,594 0.00 5 4 -20.00
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 62,863 0 -100.00 18 0 -100.00
2018-04-18 13F-HR/A FNY Partners Fund LP 14,800 14,800 0.00 4 4 0.00
2018-08-14 13F-HR VANGUARD GROUP INC 606,749 0 -100.00 174 0 -100.00
2018-08-02 13F-HR HUDSON CANYON INVESTMENT COUNSELORS LLC 6,342 0 -100.00 2 0 -100.00
2018-08-14 13F-HR Alpha Omega Wealth Management LLC 534 0 -100.00 0 0
2018-08-14 13F-HR DEUTSCHE BANK AG\ 92 0 -100.00 0 0
2018-08-08 13F-HR Manchester Capital Management LLC 28 0 -100.00 0 0
2017-01-13 13F-HR MetLife Securities, Inc 51 51 0.00 0 0
2018-09-18 13F-HR/A NORTHERN TRUST CORP 55,507 0 -100.00 16 0 -100.00
2018-08-13 13F-HR BLAIR WILLIAM & CO/IL 25,087 0 -100.00 7 0 -100.00
2018-08-14 13F-HR HighTower Advisors, LLC 15,934 0 -100.00 5 0 -100.00
2018-08-09 13F-HR BlackRock Inc. 316,734 0 -100.00 91 0 -100.00
2018-08-07 13F-HR Marathon Capital Management 11,335 0 -100.00 3 0 -100.00
2018-08-14 13F-HR Lee Financial CORP 282 0 -100.00 0 0
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 46,000 0 -100.00 13 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 2,258 0 -100.00 1 0 -100.00
2018-07-26 13F-HR Plante Moran Financial Advisors, LLC 5,000 0 -100.00 1 0 -100.00
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 166,315 0 -100.00 47 0 -100.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 241 0 -100.00 0 0
2018-07-30 13F-HR/A Virtu Financial LLC 143,401 0 -100.00 41 0 -100.00
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 0 40,990 0 59
2018-08-14 13F-HR Jefferies Group LLC 746,367 0 -100.00 214 0 -100.00
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 3,061 3,061 0.00 1 1 0.00
2018-08-14 13F-HR BARCLAYS PLC 1,471 147 -90.01 0 0
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 13,226 0 -100.00 4 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 3,531 3,531 0.00 7 5 -28.57
2018-08-14 13F-HR UBS Group AG 29,700 0 -100.00 8 0 -100.00
2018-08-13 13F-HR Advisor Group, Inc. 160 0 -100.00 0 0
CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Cytori's Chemotherapy Candidate Gets Orphan Drug Status

2018-09-18 zacks
Cytori Therapeutics (CYTX - Free Report) announced that the FDA has granted Orphan Drug designation to its chemotherapy candidate, ATI-1123, for the treatment of small cell lung cancer (“SCLC”). (5-0)

Cytori Therapeutics Inc (CYTX) CEO Marc Hedrick on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Second Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for your questions following the presentation. [Operator Instructions]

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-6)

Cytori Therapeutics Erectile Dysfunction Stem Cell Therapy Shows Positive Results in Early Trial

2018-07-09 biospace
Cytori Therapeutics, headquartered in San Diego, published data from its clinical trial of Adipose-Derived Regenerative Cells (ADRCs) in the journal Urology showing positive results.

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics First Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions] (25-1)

CUSIP: 23283K105